Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab

This submission comes after two successful phase III clinical trials conducted between 2020 and 2021.
It is estimated that in 2021 the vaccine, the most widely used against COVID-19 in the US, prevented 8.7 million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths.